Why the study?
Does a higher platelet-to-lymphocyte ratio predict worse clinical outcomes in patients with STEMI?
Does a higher platelet-to-lymphocyte ratio predict worse clinical outcomes in patients with STEMI?
Answers are grounded in this paper and cite their sources.
A higher platelet-to-lymphocyte ratio serves as a prognostic marker for increased risk of mortality and adverse cardiovascular events in patients with STEMI.
We investigated the association between platelet-to-lymphocyte ratio (PLR) and clinical outcomes (including all-cause mortality, recurrent myocardial infarction, heart failure, serious cardiac arrhythmias and ischemic stroke) in patients with ST-segment elevation myocardial infarction (STEMI). Based on PLR quartiles, 5886 patients with STEMI were categorized into 4 groups: <98.8 (n = 1470), 98.8 to 125.9 (n = 1474), 126.0 to 163.3 (n = 1478), >163.3 (n = 1464), respectively. We used Cox proportional hazards models to examine the relation between PLR and clinical outcomes. Mean duration of follow-up was 81.6 months, and 948 patients (16.1%) died during follow-up. The lowest mortality occurred in the lowest PLR quartile group ( P = 0.006), with an adjusted hazard ratio of 1.18 (95% confidence interval [CI], 1.04-1.55), 1.31 (95% CI, 1.18-1.64), and 1.59 (95% CI, 1.33-1.94) in patients with PLR of 98.8 to 125.9, 126.0 to 163.3, >163.3, respectively. Higher levels of PLR were also associated with recurrent myocardial infarction ( P trend = .023), heart failure ( P trend = .018), and ischemic stroke ( P trend = .043). In conclusion, a higher PLR was associated with recurrent myocardial infarction, heart failure, ischemic stroke, and all-cause mortality in patients with STEMI.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: